Small Cap
Healthcare / MedTech
SynPhNe
$SYPHDigitally restoring independence after stroke or brain injury using neuro-integrative wearables.
FDA-cleared wearable neurorehabilitation platform using a 3-step mind–muscle protocol proven to accelerate recovery from neurological conditions.
Liquidity
6 months
Round Type
Growth Round
Key Highlights
- FDA-cleared (Class II device)
- 400+ patients treated
- 150+ clinical trial subjects
- Revenue generated: $1M+
- Validated in US & Asia markets
- Integrated with multiple rehab hospital systems
Traction & Milestones
Patients Treated
400+
Clinical Subjects
150+
Revenue to Date
$1M+
FDA Status
Class II Cleared
About
SynPhNe develops digitally-enabled neuro-integrative wearables that restore independence after stroke or brain injury. Their FDA-cleared platform combines neuroscience with wearable technology to deliver personalized rehabilitation therapy.
Partners
Clinical Partners
Spaulding Rehabilitation HospitalTexas Children's HospitalNUHSKK HospitalNIMHANS
Strategic Partners
Enterprise SingaporeIPINational Institute of EducationNudge Sports